Head and Neck Squamous Cell Carcinoma
Conditions
Brief summary
The purpose of this study is to evaluate the results of treating patients with HPV-unrelated head and neck squamous cell carcinoma with neoadjuvant single-agent palbociclib, followed by chemoradiation (either cisplatin + IMRT or cetuximab + IMRT depending on patient characteristics), followed by adjuvant single-agent palbociclib.
Interventions
DRUGPalbociclib
Palbociclib is an oral drug available as capsules (or as liquid suspension). The capsules should be taken with food
DRUGCetuximab
-Cetuximab must not be administered as an IV push or bolus
DRUGCisplatin
-Patients will receive cisplatin via intravenous (IV) infusion over 60 minutes.
RADIATIONIntensity-Modulated Radiation Therapy
-Once daily fractions Monday through Friday, with one additional fraction of RT administered on (preferably) Fridays
PROCEDURETumor biopsy
* Tumor tissue will be collected at baseline and then after two cycles of neoadjuvant palbociclib monotherapy * If the patient has been previously enrolled in Washington University's TAP protocol (head and neck bank, HRPO #201102323), tissue that has been banked may be accessed in lieu of fresh biopsy at baseline.
PROCEDUREPeripheral blood draw
Baseline and post-treatment
Sponsors
Washington University School of Medicine
Pfizer
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Larynx SCC, hypopharynx SCC, or oral cavity SCC. HPV-unrelated OPSCC \[defined as p16INK4a negative by IHC (staining in \< 70% of cells) or HPV High Risk (Type 16 or 18) negative by ISH\]. P16INK4a positive larynx SCC, hypopharynx SCC, and oral cavity SCC are eligible given the unknown effect of this on the biology of SCC of these subsites. * Overall Stage III, IVA, or IVB disease per AJCC version 7.0 * Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with CT scan, as ≥ 20 mm by chest x-ray, or ≥ 10 mm with calipers by clinical exam. * At least 18 years of age. * Normal bone marrow function as defined below: * Absolute neutrophil count ≥ 1,000/mcL * Platelets ≥ 100,000/mcL * Hemoglobin ≥ 9.0 g/dL * QTc \< 500 msec by Fridericia * Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry, for the duration of study participation, and for 90 days after completion of treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. * Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable). Additional Cohort 1 Eligibility Criteria: Patients enrolling to Cohort 1 must meet all of the following criteria: * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Adequate organ function defined as: * Serum creatinine ≤ 1.5 x institutional upper limit of normal (IULN) and creatinine clearance ≥ 75 mL/min * Bilirubin ≤ 1.5 x IULN * ALT and AST ≤ 2.5 x IULN Additional Cohort 2 Eligibility Criteria: Patients enrolling to Cohort 2 must meet at least one of the following criteria: * ECOG performance status of 2 * Reduced organ function defined as: * Creatinine clearance 30-75 mL/min * Bilirubin 1.5-2 x IULN * ALT and AST 2.5-5 x IULN
Exclusion criteria
* Diagnosis of cutaneous, paranasal sinus, salivary, or nasopharynx SCC, or diagnosis of neck nodes with unknown primary. * Diagnosis of P16/HPV-ISH positive OPSCC. * Presence of distant metastatic disease. * Prior systemic therapy for current diagnosis of HNSCC. * A history of other malignancy ≤ 2 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or low risk/curatively treated prostate, thyroid, and cervical cancers. * Currently receiving any other investigational agents. * Treated within the last 7 days prior to Day 1 of protocol therapy with: * Food or drugs that are known to be STRONG CYP3A4 inhibitors (e.g. grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, erythromycin, clarithromycin, telithromycin, indinavir, ritonavir, nelfinavir, atazanavir, amprenavir, nefazodone, diltiazem, and delavirdine) or inducers (e.g. glucocorticoids, progesterone, rifampin, phenobarbital, St. John's wort) \[moderate CYP3A4 inhibitors/inducers are okay\] * Drugs that are known to prolong the QT interval * Drugs that are proton pump inhibitors * A history of allergic reactions attributed to compounds of similar chemical or biologic composition to palbociclib, cisplatin (for Cohort 1), or cetuximab (for Cohort 2). * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or uncontrolled electrolyte disorders that can compound the effects of a QTc-prolonging drug (e.g. hypocalcemia, hypokalemia, hypomagnesemia). * History of cirrhosis. * History of renal or liver transplant. * Pregnant and/or breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 28 days of study entry. Female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. * Known HIV-positivity and on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with palbociclib. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. * Rb (retinoblastoma) loss: mutation or homozygous deletion described on genomic sequencing report.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumor Response Rate of Newly Diagnosed p16INK4a Negative, HPV-unrelated HNSCC to Neoadjuvant Palbociclib Monotherapy | 2 cycles (56 days) | * Tumor response rate is defined as the proportion of subjects who achieve a complete response (CR) or partial response (PR) based on RECIST criteria * CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). * PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Combined Local-regional Disease Relapse Risk and Distant Metastases Risk Following Completion of CRT | Through 18 months after completion of step 2 | * Local-regional disease relapse, a binary variable (Yes vs. No). Local-regional disease relapse rate is defined as the proportion of subjects alive who have local-regional progressed disease at 18 months following completion of CRT, stratified by cohorts. * Distant metastases, a binary variable (Yes vs. No). Distant metastases rate is defined as the proportion of subjects alive who have distant metastases at 18 months following completion of CRT, stratified by cohorts. |
| Median Progression-free Survival (PFS) (Stratified by Cohort) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy | Through 5 years after completion of step 2 | -Progression-free survival (PFS), defined as the interval from the start of Step 2 (CRT) to the first documentation of disease progression or death from any cause or the end of follow-up, stratified by cohorts. |
| Progression-free Survival (PFS) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy | Through 2 years after completion of step 2 | -Progression-free survival (PFS), defined as the days from the start of Step 2 (CRT) to the first documentation of disease progression or death from any cause or the end of follow-up |
| Median Overall Survival (OS) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy | Through 5 years after completion of step 2 | -Overall survival (OS), defined as the days from the time of diagnosis to death from any cause or the end of follow-up |
| Overall Survival of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy | Through 2 years after completion of step 2 | -Overall survival (OS), defined as the days from the time of diagnosis to death from any cause or the end of follow-up |
| Change in Genomic Alterations in Tumor Tissue | At baseline and at time of disease relapse (up to 5 years) | Tumor genomic alterations at baseline and at relapse will be compared to assess for potential mechanisms of primary or secondary resistance to palbociclib. |
| Association Between Baseline Tumor CDKN2A and CCND1 Alterations and Tumor Response to Palbociclib Given Before CRT and Relapse After CRT | At baseline and at time of disease relapse (up to 5 years) | Number of participants with altered versus wild-type at baseline will be compared with response. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORDouglas R Adkins, M.D.
Washington University School of Medicine
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: Palbociclib * Step 1: Neoadjuvant palbociclib monotherapy (125 mg/day, Days 1-21 of a 28-day cycle for two cycles)
* Step 2: Cisplatin 100 mg/m\^2 given on Days 1 and 22 with accelerated IMRT 70 Gy to be administered over 6 weeks
* Step 3: Adjuvant palbociclib 125 mg/day, days 1-21 of each 28-day cycle for six cycles. Adjuvant palbociclib will begin 16 to 22 weeks following completion of cisplatin & IMRT | 19 |
| Cohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib * Step 1: Neoadjuvant palbociclib monotherapy (125 mg/day, Days 1-21 of a 28-day cycle for two cycles)
* Step 2: Cetuximab given one week before RT and then weekly with accelerated IMRT 70 Gy to be administered over 6 weeks
* Step 3: Adjuvant palbociclib 125 mg/day, days 1-21 of each 28-day cycle for six cycles. Adjuvant palbociclib will begin 16 to 22 weeks following completion of cetuximab & IMRT | 7 |
| Total | 26 |
Baseline characteristics
| Characteristic | Cohort 1: 1: Palbociclib, 2: Cisplatin & IMRT, 3: Palbociclib | Total | Cohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib |
|---|---|---|---|
| Age, Continuous | 61 years | 63 years | 66 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 19 Participants | 26 Participants | 7 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants | 4 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 16 Participants | 22 Participants | 6 Participants |
| Region of Enrollment United States | 19 participants | 26 participants | 7 participants |
| Sex: Female, Male Female | 4 Participants | 7 Participants | 3 Participants |
| Sex: Female, Male Male | 15 Participants | 19 Participants | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 26 | 0 / 18 | 1 / 7 | 0 / 19 | 8 / 26 |
| other Total, other adverse events | 26 / 26 | 18 / 18 | 7 / 7 | 19 / 19 | 0 / 0 |
| serious Total, serious adverse events | 3 / 26 | 10 / 18 | 4 / 7 | 0 / 19 | 0 / 0 |
Outcome results
Primary
Tumor Response Rate of Newly Diagnosed p16INK4a Negative, HPV-unrelated HNSCC to Neoadjuvant Palbociclib Monotherapy
* Tumor response rate is defined as the proportion of subjects who achieve a complete response (CR) or partial response (PR) based on RECIST criteria * CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Disappearance of all non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (\<10 mm short axis). * PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: 2 cycles (56 days)
Population: The data for Cohort 1 and Cohort 2 were combined as the participants enrolled in both cohorts received the same neoadjuvant palbociclib treatment (125 mg/day Days 1-21 of a 28-day cycle for two cycles) in Step 1.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Step 1 Neoadjuvant Palbociclib for Cohort 1 and Cohort 2 | Tumor Response Rate of Newly Diagnosed p16INK4a Negative, HPV-unrelated HNSCC to Neoadjuvant Palbociclib Monotherapy | 6 Participants |
Secondary
Association Between Baseline Tumor CDKN2A and CCND1 Alterations and Tumor Response to Palbociclib Given Before CRT and Relapse After CRT
Number of participants with altered versus wild-type at baseline will be compared with response.
Time frame: At baseline and at time of disease relapse (up to 5 years)
Secondary
Change in Genomic Alterations in Tumor Tissue
Tumor genomic alterations at baseline and at relapse will be compared to assess for potential mechanisms of primary or secondary resistance to palbociclib.
Time frame: At baseline and at time of disease relapse (up to 5 years)
Secondary
Combined Local-regional Disease Relapse Risk and Distant Metastases Risk Following Completion of CRT
* Local-regional disease relapse, a binary variable (Yes vs. No). Local-regional disease relapse rate is defined as the proportion of subjects alive who have local-regional progressed disease at 18 months following completion of CRT, stratified by cohorts. * Distant metastases, a binary variable (Yes vs. No). Distant metastases rate is defined as the proportion of subjects alive who have distant metastases at 18 months following completion of CRT, stratified by cohorts.
Time frame: Through 18 months after completion of step 2
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Step 1 Neoadjuvant Palbociclib for Cohort 1 and Cohort 2 | Combined Local-regional Disease Relapse Risk and Distant Metastases Risk Following Completion of CRT | Local-regional disease relapse | 0 Participants |
| Step 1 Neoadjuvant Palbociclib for Cohort 1 and Cohort 2 | Combined Local-regional Disease Relapse Risk and Distant Metastases Risk Following Completion of CRT | Distant metastases | 4 Participants |
| Step 1 Neoadjuvant Palbociclib for Cohort 1 and Cohort 2 | Combined Local-regional Disease Relapse Risk and Distant Metastases Risk Following Completion of CRT | Both local-regional disease relapse and distant metastases | 1 Participants |
| Cohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib | Combined Local-regional Disease Relapse Risk and Distant Metastases Risk Following Completion of CRT | Local-regional disease relapse | 2 Participants |
| Cohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib | Combined Local-regional Disease Relapse Risk and Distant Metastases Risk Following Completion of CRT | Distant metastases | 1 Participants |
| Cohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib | Combined Local-regional Disease Relapse Risk and Distant Metastases Risk Following Completion of CRT | Both local-regional disease relapse and distant metastases | 0 Participants |
Secondary
Median Overall Survival (OS) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy
-Overall survival (OS), defined as the days from the time of diagnosis to death from any cause or the end of follow-up
Time frame: Through 5 years after completion of step 2
Secondary
Median Progression-free Survival (PFS) (Stratified by Cohort) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy
-Progression-free survival (PFS), defined as the interval from the start of Step 2 (CRT) to the first documentation of disease progression or death from any cause or the end of follow-up, stratified by cohorts.
Time frame: Through 5 years after completion of step 2
Secondary
Overall Survival of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy
-Overall survival (OS), defined as the days from the time of diagnosis to death from any cause or the end of follow-up
Time frame: Through 2 years after completion of step 2
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Step 1 Neoadjuvant Palbociclib for Cohort 1 and Cohort 2 | Overall Survival of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy | 16 Participants |
| Cohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib | Overall Survival of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy | 5 Participants |
Secondary
Progression-free Survival (PFS) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy
-Progression-free survival (PFS), defined as the days from the start of Step 2 (CRT) to the first documentation of disease progression or death from any cause or the end of follow-up
Time frame: Through 2 years after completion of step 2
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Step 1 Neoadjuvant Palbociclib for Cohort 1 and Cohort 2 | Progression-free Survival (PFS) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy | 13 Participants |
| Cohort 2: 1: Palbociclib, 2: Cetuximab & IMRT, 3: Palbociclib | Progression-free Survival (PFS) of Patients Treated With the Three Step Sequence of Palbociclib Monotherapy, CRT, and Adjuvant Palbociclib Monotherapy | 3 Participants |